ProCE Banner Activity

Phase III TROPION-Lung01: Datopotamab Deruxtecan vs Docetaxel for Previously Treated Advanced or Metastatic NSCLC


In the phase III TROPION-Lung01 trial, a PFS benefit was observed with datopotamab deruxtecan vs docetaxel in patients with previously treated advanced or metastatic NSCLC, with the benefit primarily in nonsquamous disease.

Released: October 31, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc